The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: A systematic review of direct and indirect evidence

References

• Schon MP, Boehncke WH. Psoriasis. N Eng J Med 2005;353:1899-1912
   PubMedGoogle Scholar
• van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31-6
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-34
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400
   PubMed Web of Science ®Google Scholar
• Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-7
   Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
   PubMed Web of Science ®Google Scholar
• Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7
   PubMed Web of Science ®Google Scholar
• Chan CS, van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Am Acad Dermatol 2009;60:962-71
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65
   PubMedGoogle Scholar
• Papp K, Berth-Jones, J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereal 2007;21:1151-60
   PubMed Web of Science ®Google Scholar
• Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study. Dermatology 2008;217:107-13
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomised, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof P, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Br J Dermatol 2009;160:170-6
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis. Br J Dermatol 2009;161:159-66
   PubMed Web of Science ®Google Scholar
• Tyring S, Appell M, Bibby A, et al. Calcipotriene/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients. J Am Acad Dermatol 2008;58(2 Suppl. 2):AB125
   Web of Science ®Google Scholar
• Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomised, 8 week, double-blind phase of a clinical trial. Int J Dermatol 2010;49:1328-33
   Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-8
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Ganslandt C, Tan J, et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009;23:919-26
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:Appendix 2
   Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP): Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. EMEA, London, 18 November 2004. Available at: http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf [Last accessed 29 March 2010]
   Google Scholar
• Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515
   Google Scholar
• NICE Guide to the methods of technology Appraisal (NICE June 2008). Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed 29 March 2010]
   Google Scholar
• Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Affleck AG, Bottomley JM, Auland ME, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:251-68
   Google Scholar
• Smith DRW, Bottomley JM. Auland ME, et al. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:239-49
   Google Scholar
• Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000;20:65-8
   PubMedGoogle Scholar
• Feldman SR, Ravis SM, Fleischer AB Jr, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001;5:386-9
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Finlay AY, Fleming CJ, et al. A randomised, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006;17:90-5
   PubMed Web of Science ®Google Scholar
• Hillström L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp. J Int Med Res 1982;10:419-22
   PubMed Web of Science ®Google Scholar
• Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12% BMV foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: Quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002;15:27-30
   Google Scholar
• Monk BE, Mason RBS, Munro CS, et al. An open and single-blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. J Dermatol Treat 1995;6:159-61
   Web of Science ®Google Scholar
• Andreassi L, Giannetti A, Milani M, et al. Scale Investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003;148:134-8
   PubMed Web of Science ®Google Scholar
• Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects QOL: a randomised single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72:407-11
   PubMed Web of Science ®Google Scholar
• Høvding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981;3:61-6
   PubMedGoogle Scholar
• Mazzotta A, Esposito M, Carboni I, et al. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat 2007;18:84-7
   PubMed Web of Science ®Google Scholar
• Thaci D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153-6
   PubMed Web of Science ®Google Scholar
• Duweb G, Alhaddar J, Abuhamida M. Caclipotriol solution in scalp psoriasis. Int J Tissue Reaction 2005;27:163-6
   PubMedGoogle Scholar
• Ross SD, Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981;28:438-9
   PubMed Web of Science ®Google Scholar
• Sulzberger MB, Obadia J. A modified liquid petrolatum preparation; its use in the management of certain common dermatoses of the scalp. AMA Arch Derm 1956;73:373-5
   PubMedGoogle Scholar
• Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983;32:290-6
   PubMed Web of Science ®Google Scholar
• Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7
   PubMed Web of Science ®Google Scholar
• Clinical Study Report. Comparative effects of calcipotriol (MC 903) solution (50 µg/ml) and placebo solution (vehicle of MC 903 solution) in the treatment of scalp psoriasis. A multicentre, prospective randomized double-blind vehicle controlled parallel group study. MC 1190 STUDY. 21 December 1992. Data on file. LEO Pharma
   Google Scholar
• Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-32
   PubMed Web of Science ®Google Scholar
• Curley RK, Vickers Cfh, Norris T, et al. A comparative study of BDP with salicylic acid and BMV for the treatment of steroid-responsive dermatoses of the scalp. J Derm Treat 1990;1:203-6
   Google Scholar
• Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000;39:535-8
   PubMed Web of Science ®Google Scholar
• Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995;17:390-401
   PubMed Web of Science ®Google Scholar
• Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomised comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatol Treat 2005;16:31-6
   PubMed Web of Science ®Google Scholar
• Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3:367-73
   PubMedGoogle Scholar
• Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-7
   PubMed Web of Science ®Google Scholar
• Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83
   PubMed Web of Science ®Google Scholar
• Clinical Study Report. Calcipotriol scalp solution II in psoriasis. Efficacy and safety of calcipotriol scalp solution II in scalp psoriasis. A multicentre, prospective, randomized, double-blind, vehicle-controlled, comparative study with 3 parallel groups: calcipotriol scalp solution II 50 µg/ml, calcipotriol scalp solution 50 µg/ml and vehicle of scalp solution II. MCW 9603 INT Study. 10 July 2000
   Google Scholar
• Barrett C, Lowsen D, Blades KJ. Limited benefit of combined use of tar-based shampoo with 50µg/ml calcipotriol solution in scalp psoriasis. J Dermatol Treat 2005;16:175
   PubMed Web of Science ®Google Scholar
• Klaber MR, McKinnon C. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal) shampoo, and long-term experience. J Dermatol Treat 2000;11:21-8
   Web of Science ®Google Scholar